Stock Events

Stock Events

Akari Therapeutics 

$8.18
12
-$0.06-0.73% 19:24 Today

Statistics

Day High
8.4
Day Low
8.03
52W High
33.6
52W Low
3.02
Volume
9,359
Avg. Volume
62,825
Mkt Cap
18.69M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

Apr 1Expected
Q2 2022
Q4 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-0.1
-0.06
-0.03
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-17.3MNet Income

Analyst Ratings

$30.00Average Price Target
The highest estimate is ⁦30.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AKTX. It's not an investment recommendation.
Tesla
4
TSLA
Schwab US Dividend Equity
3
SCHD
Vanguard S&P 500
3
VOO
SNDL
3
SNDL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals engages in developing treatments for cystic fibrosis and other serious diseases, overlapping with Akari's focus on rare diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals specializes in developing medications for eye diseases, rare diseases, and immune disorders, competing in similar therapeutic areas as Akari.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurology, rare diseases, and autoimmune disorders, areas that overlap with Akari's therapeutic focus.
AMGEN
AMGN
Mkt Cap251.94B
Amgen develops treatments for serious illnesses in areas like oncology and cardiology, and its work in immune disorders competes with Akari.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences focuses on antiviral drugs, liver diseases, and inflammatory and respiratory diseases, competing in the broader area of serious and rare diseases.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie works on chronic autoimmune diseases and more, with its broad focus on serious diseases including areas that compete with Akari's treatments.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk specializes in diabetes and obesity but is expanding into rare blood disorders, which could compete with Akari's pipeline.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad portfolio including treatments for rare diseases and inflammation, making it a competitor in some of Akari's key areas.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for a wide range of diseases, including those in competition with Akari's focus areas.

About

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Show More
CEO
Abizer Gaslightwala
Employees
5
Country
United States
ISIN
US00972G4055
WKN
000A4270Y

Listings

STU
DE
CLA1.STU
MU
DE
CLAB.MU
MU
DE
CLA1.MU
XNAS
US
AKTX

0 Comments

Share your thoughts

FAQs

What is Akari Therapeutics stock price today?▼
The current price of AKTX is $8.18 USD — it has decreased by -0.73% in the past 24 hours. Watch Akari Therapeutics stock price performance more closely on the chart.
What is Akari Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Akari Therapeutics stocks are traded under the ticker AKTX.
Is Akari Therapeutics stock price growing?▼
AKTX stock has risen by +6.03% compared to the previous week, the month change is a -7.22% fall, over the last year Akari Therapeutics has showed a -73.03% decrease.
What is Akari Therapeutics market cap?▼
Today Akari Therapeutics has the market capitalization of 18.69M
What is Akari Therapeutics revenue for the last year?▼
Akari Therapeutics revenue for the last year amounts to 0 USD.
What is Akari Therapeutics net income for the last year?▼
AKTX net income for the last year is -17.3M USD.
How many employees does Akari Therapeutics have?▼
As of November 2, 2026, the company has 5 employees.
In which sector is Akari Therapeutics located?▼
Akari Therapeutics operates in the Health & Wellness sector.
When did Akari Therapeutics complete a stock split?▼
The last stock split for Akari Therapeutics was on March 31, 2026 with a ratio of 1:40.
Where is Akari Therapeutics headquartered?▼
Akari Therapeutics is headquartered in TAMPA, United States.